Dr. Nathan Bryan

We published in 2011 that nitric oxide production is necessary for insulin signaling. If the cell can't make nitric oxide, you develop insulin resistance. So diabetes, a global pandemic. Nine out of ten Americans are metabolically unfit. The other thing is exercise intolerance.

We published in 2011 that nitric oxide production is necessary for insulin signaling. If the cell can't make nitric oxide, you develop insulin resistance. So diabetes, a global pandemic. Nine out of ten Americans are metabolically unfit. The other thing is exercise intolerance.

If you try to start an exercise regimen and you can't walk up a flight of steps or exercise moderately for 15, 20, 30 minutes, then you're nitric oxide deficient. And then the other one is obviously Alzheimer's because Alzheimer's is a vascular disease. It's reduced blood flow to the brain, what we call focal ischemia. There's insulin resistance. Alzheimer's has been called diabetes type 3.

If you try to start an exercise regimen and you can't walk up a flight of steps or exercise moderately for 15, 20, 30 minutes, then you're nitric oxide deficient. And then the other one is obviously Alzheimer's because Alzheimer's is a vascular disease. It's reduced blood flow to the brain, what we call focal ischemia. There's insulin resistance. Alzheimer's has been called diabetes type 3.

So you can't get glucose into the cell, and that's the primary energy source or substrate of the brain. Oxidative stress and immune dysfunction. And then you get misfolded proteins, and that shows up as the tau tangles and the amyloid plaque that we see in Alzheimer's patients. So if we can restore—and nitric oxide corrects every single thing we know about Alzheimer's.

So you can't get glucose into the cell, and that's the primary energy source or substrate of the brain. Oxidative stress and immune dysfunction. And then you get misfolded proteins, and that shows up as the tau tangles and the amyloid plaque that we see in Alzheimer's patients. So if we can restore—and nitric oxide corrects every single thing we know about Alzheimer's.

It improves blood flow to the brain. It improves glucose uptake, so it overcomes the metabolic aspect of Alzheimer's. It reduces inflammation. In fact, a number of my patents are on a method of reducing inflammation. It inhibits the oxidative stress we see in Alzheimer's and neurological disease, and it prevents the immune dysfunction.

It improves blood flow to the brain. It improves glucose uptake, so it overcomes the metabolic aspect of Alzheimer's. It reduces inflammation. In fact, a number of my patents are on a method of reducing inflammation. It inhibits the oxidative stress we see in Alzheimer's and neurological disease, and it prevents the immune dysfunction.

And when you do that, when you restore blood flow and you get nutrients and oxygen in and you take out the metabolic waste products, there's no misfolding of protein. So you don't get the amyloid plaque. You don't get the tau tangles. So this simple molecule, nitric oxide gas, I'm absolutely convinced will eradicate and cure Alzheimer's.

And when you do that, when you restore blood flow and you get nutrients and oxygen in and you take out the metabolic waste products, there's no misfolding of protein. So you don't get the amyloid plaque. You don't get the tau tangles. So this simple molecule, nitric oxide gas, I'm absolutely convinced will eradicate and cure Alzheimer's.

Because it addresses every physiological root cause of Alzheimer's.

Because it addresses every physiological root cause of Alzheimer's.

No, I think that's a very key because the success or failure of any clinical trial, any drug in any clinical trial is dependent upon the design of the clinical trial and what patients at what stage of disease that you enroll these patients. So what are the inclusion criteria and what are the exclusion criteria?

No, I think that's a very key because the success or failure of any clinical trial, any drug in any clinical trial is dependent upon the design of the clinical trial and what patients at what stage of disease that you enroll these patients. So what are the inclusion criteria and what are the exclusion criteria?

And there's a stage in every disease, whether it's heart disease, kidney disease, Alzheimer's, where you've reached a point of no return. There's really no medical therapy that's going to reverse that disease because it's progressed to a state that's irreversible.

And there's a stage in every disease, whether it's heart disease, kidney disease, Alzheimer's, where you've reached a point of no return. There's really no medical therapy that's going to reverse that disease because it's progressed to a state that's irreversible.

So I think what we try to do is take patients early in the process, what we call vascular dementia, mild cognitive impairment, early Alzheimer's. Because what I want to be able to demonstrate is two things. Number one, can we stop the progression of disease? Once it's started, can we stop the progression?

So I think what we try to do is take patients early in the process, what we call vascular dementia, mild cognitive impairment, early Alzheimer's. Because what I want to be able to demonstrate is two things. Number one, can we stop the progression of disease? Once it's started, can we stop the progression?

And then number two is we want to enroll patients far enough along to where we can show regression. So can you move the needle back? And so that's a very kind of a specific and finite patient population. When you design a clinical study, number one, at the absolute worst, we want to stop progression. At the absolute best, we want to show that we can regress disease.

And then number two is we want to enroll patients far enough along to where we can show regression. So can you move the needle back? And so that's a very kind of a specific and finite patient population. When you design a clinical study, number one, at the absolute worst, we want to stop progression. At the absolute best, we want to show that we can regress disease.